Bamco Inc. NY Lowers Position in Repligen Co. (NASDAQ:RGEN)

Bamco Inc. NY reduced its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 4.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 160,227 shares of the biotechnology company's stock after selling 6,792 shares during the period. Bamco Inc. NY owned approximately 0.29% of Repligen worth $23,063,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in shares of Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after buying an additional 743,815 shares in the last quarter. Groupama Asset Managment raised its position in Repligen by 12,321.0% in the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after acquiring an additional 400,680 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Repligen during the 4th quarter worth $53,428,000. Raymond James Financial Inc. acquired a new position in shares of Repligen during the 4th quarter worth $52,492,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock worth $65,395,000 after purchasing an additional 203,011 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity

In related news, Director Margaret Pax bought 250 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of research analyst reports. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective for the company. Canaccord Genuity Group decreased their target price on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Finally, TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Stock Performance

NASDAQ:RGEN opened at $141.51 on Monday. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The firm has a 50 day simple moving average of $137.82 and a 200-day simple moving average of $145.89. The firm has a market cap of $7.95 billion, a PE ratio of -277.47, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business's revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 earnings per share. On average, equities analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.